Table 2.

Effects of anti-miR-10b on cisplatin-induced cell growth inhibition in CD44v3^highALDH1^high cells following 200 kDa-HA treatment.

Treatments	Cisplatin-induced tumor cell growth inhibition IC50 (µM)* (% of control)
Negative miRNA control-treated cells (control) (No HA)	2.00 ± 0.15 (100.00%)
Negative miRNA control-treated cells (+200 kDa-HA)	5.75 ± 0.14 (288.00%)
Anti-miR-10-treated cells (No HA)	1.58 ± 0.22 (0.79%)
Anti-miR-10b-treated cells (+200 kDa-HA)	1.58 ± 0.23 (0.79%)

^*Tumor cell growth inhibition (IC₅₀) is designated as “the µM concentration of chemotherapeutic drug (e.g., cisplatin treatment) that causes 50% inhibition of tumor cell growth” using CellTiter-Glo Luminescent Cell Viability Assay as described in Section 2. IC₅₀ values are presented as the means ± standard deviation. All assays consisted of at least six replicates and were performed on at least 3–5 different experiments.